IL4 and asthma: As such, IL-4 and IL-13 signaling antagonists (e.g., dupilumab) have proven to be highly successful commercially, and several therapeutics targeting STAT6 directly, including small peptide inhibitors of the SH2 domain of STAT5 and STAT6 (10), have been evaluated and shown to be successful in preclinical studies of experimental asthma.